US 11,684,658 B2
Vaccine adjuvants and formulations
Vincent K. Tuohy, Broadview Heights, OH (US); and Justin M. Johnson, Willoughby Hills, OH (US)
Assigned to CLEVELAND CLINIC FOUNDATION, Cleveland, OH (US)
Appl. No. 16/641,819
Filed by The Cleveland Clinic Foundation, Cleveland, OH (US)
PCT Filed Feb. 13, 2020, PCT No. PCT/US2020/018186
§ 371(c)(1), (2) Date Feb. 25, 2020,
PCT Pub. No. WO2020/168126, PCT Pub. Date Aug. 20, 2020.
Claims priority of provisional application 62/806,422, filed on Feb. 15, 2019.
Prior Publication US 2021/0386839 A1, Dec. 16, 2021
Int. Cl. A61K 39/00 (2006.01); A61P 35/00 (2006.01); A61K 33/243 (2019.01); A61K 9/107 (2006.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/4196 (2006.01); A61K 31/502 (2006.01); A61K 31/675 (2006.01); A61K 31/704 (2006.01); A61K 31/7048 (2006.01); A61K 31/7068 (2006.01); A61K 38/14 (2006.01); A61K 39/39 (2006.01); A61K 45/06 (2006.01); A61K 47/44 (2017.01)
CPC A61K 39/0011 (2013.01) [A61K 9/107 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/4196 (2013.01); A61K 31/502 (2013.01); A61K 31/675 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 31/7068 (2013.01); A61K 33/243 (2019.01); A61K 38/14 (2013.01); A61K 39/39 (2013.01); A61K 45/06 (2013.01); A61K 47/44 (2013.01); A61P 35/00 (2018.01); A61K 2039/545 (2013.01); A61K 2039/55583 (2013.01)] 10 Claims
 
1. A composition comprising:
(a) a tumor-associated antigen;
(b) zymosan;
(c) mineral oil; and
(d) mannide monooleate.